KRTAP11-1: A Potential Drug Target with Unique Properties and Functions

Target Name: KRTAP11-1

NCBI ID: G337880

KRTAP11-1

KRTAP11-1: A Potential Drug Target with Unique Properties and Functions

KRTAP11-1 (HACL1) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the known as the KRTAP family, which consists of four similar proteins that are involved in various cellular processes, including cell signaling, cytoskeletal organization, and neurotransmitter release.

One of the unique features of KRTAP11-1 is its ability to interact with various signaling molecules, including G protein-coupled receptors (GPCRs) and voltage-gated ion channels (VGICs). This interaction between KRTAP11-1 and these molecules makes it an attractive target for drug development.

KRTAP11-1 has been shown to play a role in various physiological processes, including cell survival, migration, and intracellular signaling. For example, studies have shown that KRTAP11-1 can interact with and modulate the activity of the protein p21, which is a negative regulator of the cell cycle. This interaction between KRTAP11-1 and p21 suggests that KRTAP11-1 may be involved in regulating cell cycle progression and may be a potential drug target.

Another study has shown that KRTAP11-1 can interact with the GPCR protein GPR83, which is involved in cell signaling and neurotransmission. This interaction between KRTAP11-1 and GPR83 suggests that KRTAP11-1 may be involved in neurotransmitter release and signaling, which could make it a potential drug target for attention deficit hyperactivity disorder (ADHD) and other neuropsychiatric conditions.

In addition to its potential role in neurotransmission and signaling, KRTAP11-1 has also been shown to play a role in cell survival and cytoskeletal organization. Studies have shown that KRTAP11-1 can interact with and modulate the activity of the protein Bcl-2, which is involved in cell survival and cytoskeletal organization. This interaction between KRTAP11-1 and Bcl-2 suggests that KRTAP11-1 may be involved in regulating cell survival and cytoskeletal organization, which could make it a potential drug target for various diseases, including cancer.

Given the unique combination of properties and functions that KRTAP11-1 exhibits, it is an attractive target for drug development. Studies are currently being conducted to determine the full range of functions and potential drug targets for KRTAP11-1. In addition to its potential as a drug target, KRTAP11-1 is also being studied for its potential use as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, KRTAP11-1 (HACL1) is a protein that has a unique combination of properties and functions that make it an attractive target for drug development. Its ability to interact with various signaling molecules, including GPCRs and VGICs, as well as its role in cell survival, migration, and intracellular signaling, make it a promising candidate for drug targeting. Additionally, KRTAP11-1 has also been shown to play a role in neurotransmission and signaling, which could make it a potential drug target for various neuropsychiatric conditions. Further studies are needed to fully determine the full range of functions and potential drug targets for KRTAP11-1, as well as its potential use as a biomarker for various diseases.

Protein Name: Keratin Associated Protein 11-1

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP11-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP11-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets